News

As per the agreement, Hovione and PSI will bring their spray-drying based sloid solution technologies to maximize the bioavailability of BCS Class II active pharmaceutical ingredients. Development will

In a Phase IIb open-label trial evaluating infants at 2, 4, 6 months or at 2, 3, 4 months with or without routine vaccines, Bexsero demonstrated that the

Previously, DMC asked Merck to terminate patient recruitment as the study failed to meet the formal futility criteria. The decision was based on the data which showed overall

TargetRx, through its AdvantageBuilder database of more than 300 million questions answered by over 80,000 physicians, has identified 11 attributes, or Y-Factors, that motivate physicians to prescribe. The

With this partnership, LSK can implement and support Medidata Rave across all trial phases, sizes and locations and offer sponsors and investigators the ability to reduce delays and

ANVISA provides regulatory approval for drugs and other products seeking to enter the large and growing Brazilian market. In addition to ANVISA certification, Celerion’s Belfast facility has also

ICT-107 is the company’s dendritic cell based cancer vaccine candidate that targets multiple tumor antigens for the treatment of glioblastoma multiforme (GBM). ImmunoCellular’s double-blind, placebo-controlled, 2:1 randomized Phase

CEQ508 is intended to be used as a treatment for reducing the levels of beta-catenin protein in the epithelial cells of the small and large intestine. In the

AVL-192 is an oral compound that silences the HCV protease (NS3) through irreversible covalent bonding to the target protein. Preclinical data presented by Avila demonstrated that it selectively